Free Trial

Invizyne Technologies Inc.'s (NASDAQ:IZTC) Lock-Up Period Set To Expire on May 12th

Invizyne Technologies logo with Medical background

Invizyne Technologies' (NASDAQ:IZTC - Get Free Report) lock-up period will end on Monday, May 12th. Invizyne Technologies had issued 1,875,000 shares in its IPO on November 13th. The total size of the offering was $15,000,000 based on an initial share price of $8.00. Shares of the company owned by company insiders and major shareholders will be eligible for trade following the end of the lock-up period.

Invizyne Technologies Stock Performance

Shares of IZTC opened at $10.89 on Monday. The firm's fifty day moving average is $12.85. Invizyne Technologies has a 1-year low of $8.50 and a 1-year high of $23.00.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the company. BNP Paribas Financial Markets purchased a new stake in Invizyne Technologies in the fourth quarter valued at approximately $35,000. Geode Capital Management LLC purchased a new stake in shares of Invizyne Technologies in the 4th quarter valued at $277,000. Finally, Citadel Advisors LLC acquired a new stake in shares of Invizyne Technologies in the fourth quarter worth $456,000.

Invizyne Technologies Company Profile

(Get Free Report)

Invizyne Technologies Inc is a cell-free enzyme-based biomanufacturing technology company. It redefining biomanufacturing by leveraging cell-free, multi-step, enzyme-based systems to efficiently transform natural or renewable resources into highly sought after biochemicals. Invizyne Technologies Inc is based in Monrovia, CA.

Further Reading

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Invizyne Technologies Right Now?

Before you consider Invizyne Technologies, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Invizyne Technologies wasn't on the list.

While Invizyne Technologies currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

A Beginner's Guide to Investing in Cannabis Cover

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Buy Early: 3 Tech Trends With Millionaire-Making Potential
SMCI Stumbles on Earnings: Why Some Investors Still Want In
5 Stocks to BUY NOW in May 2025

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines